Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial
VKTX•VKTX•VKTX•VKTX•Viking Therapeutics said 74% of participants taking VK2735 improved their obesity classification over 13 weeks in its Phase 2 VENTURE trial, outperforming placebo. The company is evaluating weekly injectable VK2735 in its ongoing Phase 3 VANQUISH program, with completion expected in 2027.
Viking Therapeutics presented new results from its Phase 2 VENTURE obesity trial of injectable VK2735 at ObesityWeek 2026. Over 13 weeks, 74% of treated participants improved their obesity classification, outperforming placebo, and none shifted to a higher BMI category.
Participants whose obesity classification improved showed greater reductions in cardiovascular and metabolic risk markers than those whose classification remained unchanged. The ongoing Phase 3 VANQUISH program evaluates weekly injectable VK2735, with trial completion expected in 2027.
